Hpylori kit
Reading File
Finding Sources
Searching PubMed
"Helicobacter pylori" AND eradication AND treatment
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Searching the Web
H pylori eradication kit Prevpac Helidac Pylera Talicia 2024 2025 treatment regimens
Reading Web Page
H pylori eradication kit treatment regimens ACG guidelines
Here is a comprehensive overview of H. pylori eradication kits (treatment regimens):
H. pylori Eradication — Overview
Helicobacter pylori is a urease-producing gram-negative bacterium implicated in chronic gastritis, peptic ulcer disease, MALT lymphoma, and gastric adenocarcinoma (WHO Class I carcinogen). Eradication is defined as a negative test ≥4 weeks after completing therapy.
Indications for Eradication
- Active or previously documented peptic ulcer disease (strongest indication)
- Gastric MALT lymphoma
- Uninvestigated dyspepsia in high-prevalence areas (>10–20%) — test-and-treat strategy
- After endoscopic resection of early gastric cancer
- First-degree relatives of gastric cancer patients
Pre-packaged "Kits" / Combination Products
| Kit Name | Contents | Notes |
|---|---|---|
| PrevPac | Lansoprazole 30 mg + Amoxicillin 500 mg + Clarithromycin 500 mg — each BID × 14 days | Classic triple therapy |
| Omeclamox-Pak | Omeprazole 20 mg + Clarithromycin 500 mg + Amoxicillin 1,000 mg — each BID | Comparable to PrevPac |
| Helidac | Bismuth subsalicylate 262.4 mg + Metronidazole 250 mg + Tetracycline 500 mg — each QID × 14 days | Requires concurrent PPI |
| Pylera | Bismuth subcitrate potassium + Metronidazole + Tetracycline HCl — QID × 10 days | Taken with PPI; bismuth-based quadruple |
| Talicia | Omeprazole 10 mg + Amoxicillin 250 mg + Rifabutin 12.5 mg — TID × 14 days | For clarithromycin/metronidazole-resistant or treatment-experienced patients |
| Voquezna Dual Pak | Vonoprazan 20 mg + Amoxicillin 1 g — each BID × 14 days | PCAB-based; approved Dec 2023 |
| Voquezna Triple Pak | Vonoprazan 20 mg + Amoxicillin 1 g + Clarithromycin 500 mg — each BID × 14 days | PCAB-based triple therapy |
PCAB = potassium-competitive acid blocker. Vonoprazan provides more potent, sustained acid suppression than PPIs and is not affected by CYP2C19 polymorphisms.
Standard Regimens (2024 ACG Guideline Update)
1. Bismuth Quadruple Therapy (BQT) — Preferred First-Line (empiric)
PPI (double dose, e.g., omeprazole 40 mg BID) + Bismuth + Tetracycline + Metronidazole (or tinidazole) × 14 days
- Eradication rate: ~85–90%
- Preferred when clarithromycin resistance is unknown or likely >15%
- Corresponds to the Pylera/Helidac kit approach
2. PPI Triple Therapy — still acceptable in low-resistance areas
PPI BID + Clarithromycin 500 mg BID + Amoxicillin 1 g BID × 14 days
- Effective where clarithromycin resistance <15% (Northern Europe, parts of North America)
- PrevPac / Omeclamox-Pak kits
- Eradication rate: ~75–90% (falling due to rising clarithromycin resistance)
3. Rifabutin Triple Therapy (Talicia) — alternative first-line / salvage
Omeprazole + Amoxicillin + Rifabutin × 14 days
- Effective against clarithromycin- and metronidazole-resistant strains
- Avoid in mycobacterial disease; can cause myelosuppression
4. Vonoprazan-Based Therapy — alternative first-line
Vonoprazan + Amoxicillin ± Clarithromycin × 14 days
- Superior to PPI-clarithromycin triple therapy in the PHALCON-HP Phase 3 trial
- Particularly useful in CYP2C19 rapid metabolizers
5. Non-Bismuth Quadruple (Concomitant) Therapy
PPI + Clarithromycin + Amoxicillin + Metronidazole × 14 days
- Eradication rate: ~90% for 14 days
- Overcomes metronidazole resistance partially
6. Sequential Therapy
PPI + Amoxicillin × 5 days → PPI + Clarithromycin + Metronidazole × 5 days
- 10-day sequential ≈ 14-day triple therapy
Second-Line / Salvage Therapy
| Previous regimen | Preferred salvage |
|---|---|
| Triple therapy (clarithromycin-based) | Bismuth quadruple (BQT) × 14 days |
| Bismuth quadruple | Levofloxacin-based quadruple (with bismuth) × 10–14 days |
| Multiple failures | Antibiotic susceptibility testing + culture-guided therapy |
Key Principles
- Test before treating: Urea breath test (UBT) or stool antigen (HpSA) preferred in community; serology has low specificity and cannot confirm eradication
- Confirm eradication with UBT, stool antigen, or biopsy ≥4 weeks after therapy (stop PPIs 1–2 weeks before)
- Antibiotic resistance is the main cause of failure: clarithromycin resistance 10–50% globally; metronidazole 20–80%; levofloxacin up to 50%
- Adherence is critical — courses are 10–14 days with multiple daily doses
- Reinfection after successful eradication is rare (<1%/year in developed settings)
Resistance Pattern Guidance (2024 ACG)
| Clarithromycin resistance locally | Recommended first-line |
|---|---|
| <15% | Triple therapy or BQT |
| ≥15% or unknown | BQT (preferred) or rifabutin triple / vonoprazan dual |
Sources: Goldman-Cecil Medicine; Bailey & Love's Surgery; Yamada's Textbook of Gastroenterology; Textbook of Family Medicine; ACG 2024 Guideline (UIC DIG, Jan 2025); recent meta-analyses: Ford AC et al. Gastroenterology 2025 [PMID 39824392]; Zhang Y et al. Ann Med 2025 [PMID 40697099].
This is a shared conversation. Sign in to Orris to start your own chat.